i recently bought some shares in this company. Most likely catalysts for re-rate are likely to be, in no particular order:
1) directors buying
2) benchmarking done comparing market cap of this company versus market cap of other therapeutic companies at the same stage.
3) nearing completion of phase 3 trials (i think this will take another 18 months roughly...I THINK)
Keen to hear others thoughts. As always this is a high risk high reward company.
cheers
i recently bought some shares in this company. Most likely...
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
